GEN Exclusives

More »

GEN News Highlights

More »
Jan 4, 2010

Cancer Research UK to Conduct Phase I Trial with Merck KGaA’s B-Cell Lymphoma Candidate

  • Cancer Research UK and Cancer Research Technology, the charity’s development and commercialization arm, are taking over preclinical and early clinical development of Merck KGaA’s leukemia and lymphoma candidate called DI-B4.

    Cancer Research UK will fund a Phase I trial with DI-B4, a CD19-targeting mAb. Merck retains the option to take the antibody through later-stage clinical development and commercialization in return for future payments to the charity. If the company decides not to exercise this option, Cancer Research Technology will be given rights to the antibody to look for other partnership opportunities.

    DI-B4 will be one of the first drugs manufactured at Cancer Research UK’s new £20 million (about $32.33 million) Biotherapeutic Development Unit. It was designed for the development and GMP manufacture of biotherapeutics including viruses for clinical trials. The Phase I trial with Dl-B4 will involve about 20 to 40 patients with advanced B-cell lymphoma.

    The deal comes under Cancer Research UK’s Clinical Development Partnership program. The center says that DI-B4 is the fourth anticancer drug to enter this program, which was established in 2006.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »